Search Results
Jul 22, 2026, 19:03 ET Samsung Biologics Reports Second Quarter 2026 Financial Results
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes,
More news about: Samsung Biologics
Jul 22, 2026, 11:38 ET Airlift Bioreactors Market to Reach USD 8.20 Billion by 2035 as Biopharmaceutical Production and Single-Use Bioprocessing Drive Industry Growth | Future Market Insights
https://www.futuremarketinsights.com/reports/organoids-market mRNA Synthesis Raw Materials Market - https://www.futuremarketinsights.com/reports/mrna-synthesis-raw-materials-market In-vitro Human Models
More news about: Future Market Insights
Jul 21, 2026, 08:30 ET AllerGene AI Therapeutics Founder and CEO Sid Kerkar to Present In Vivo Mast Cell-Targeting CAR Technology at Hanson Wade Summit
advances in cell therapy, RNA delivery, and the biology of allergic diseases to engineer immune cells directly in the body using mRNA-LNP technology. The company is developing novel mRNA CAR constructs that selectively target human mast cells and is evaluating transient, controllable, and repeatable in vivo
More news about: AllerGene AI Therapeutics
Jul 20, 2026, 09:00 ET Argo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012
as our clinical trials progress," said Dr. Dongxu Shu, Co-founder and CEO of Argo Biopharma.BW-41012 is an siRNA therapeutic that targets FXI mRNA. The Phase I study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study designed to evaluate the safety, tolerability,
More news about: Argo Biopharmaceutical Co., Ltd
Jul 20, 2026, 01:32 ET Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Jul 19, 2026, 18:43 ET Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Jul 16, 2026, 10:30 ET Oligonucleotide Synthesis Market worth $32.72 billion by 2031 - Exclusive Report by MarketsandMarkets™
therapies are requiring custom-engineered single-guide RNAs, metagenomic sequencing is compelling the production of extensive parallel custom libraries, and mRNA-based therapeutic vaccines are scaling to commercial volumes. Consequently, synthesis providers must strategically transition from legacy laboratory-scale
More news about: MarketsandMarkets
Jul 15, 2026, 09:00 ET Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology
enzymes for mRNA manufacturing; and PeliCRM197®: a commercially validated
More news about: Primrose Bio
Jul 15, 2026, 08:47 ET Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
spinal motor neurons.Durable Knockdown in NHPs: In cynomolgus monkeys, intrathecal RAG-17 achieved up to 91% reduction of SOD1 mRNA in the lumbar spinal cord, an effect that persisted for up to 72 days post-dose, suggesting the potential for significantly extended dosing intervals
More news about: Ractigen Therapeutics
Jul 15, 2026, 05:56 ET Skyhawk Therapeutics gibt die Ausweitung seiner globalen zulassungsrelevanten klinischen Studie „FALCON-HD" für SKY-0515 zur Behandlung der Huntington-Krankheit auf die Vereinigten Staaten, Kanada und das Vereinigte Königreich bekannt
bei gesunden Probanden und Teilnehmern mit Huntington-Krankheit (HD) im Frühstadium zu bewerten sowie Biomarker wie das mutierte HTT-Protein und PMS1-mRNA sowie Wirksamkeitsendpunkte wie den cUHDRS und dessen Teilkomponenten „Total Functional Capacity" (TFC), Total Motor Score (TMS), Symbol-Digit-Modalities-Test
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:36 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
healthy volunteers and participants with early-stage Huntington's disease (HD), as well as to assess biomarkers including mutant HTT protein and PMS1 mRNA, and efficacy endpoints including cUHDRS and its subcomponents Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:17 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
healthy volunteers and participants with early-stage Huntington's disease (HD), as well as to assess biomarkers including mutant HTT protein and PMS1 mRNA, and efficacy endpoints including cUHDRS and its subcomponents Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test
More news about: Skyhawk Therapeutics
Jul 14, 2026, 07:50 ET Former Client and Three-Decade Data Sciences Leader John Reynders, PhD, Joins Rancho BioSciences Leadership on Board of Directors
Moderna Therapeutics, where he created a fully cloud-based enterprise infrastructure and developed the informatics solutions that enabled the design of mRNA therapeutics. He has also served as Vice President of R&D Information at AstraZeneca and held senior leadership roles at Johnson & Johnson,
More news about: Rancho BioSciences
Jul 14, 2026, 06:30 ET Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation, potentially leading to improved heart function.About
More news about: Atrium Therapeutics
Jul 14, 2026, 04:18 ET Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Jul 13, 2026, 10:49 ET Acidity Regulators Market to Hit $14.22 Billion by 2031, Driven by Food Safety Compliance & Clean-Label Reformulation - Mordor Intelligence
clean-label consumer trends. Meanwhile, the high-margin pharmaceutical sector is expanding its use of lipid-based delivery vehicles to optimize advanced mRNA therapeutics, oncology products, and biocompatible skincare serums. About Mordor Intelligence: Mordor Intelligence is a trusted
More news about: Mordor Intelligence Private Limited
Jul 12, 2026, 12:00 ET A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
RNA Inc. is a Calgary, Alberta-based contract development and manufacturing organization specializing in GMP-grade nucleic acid products including mRNA, plasmid DNA, lipid formulations and drug product fill and finish. Northern RNA is committed to building world-class Canadian biomanufacturing capacity
More news about: HDT Bio Corp.
Jul 09, 2026, 13:06 ET GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases
frontier AI models and its scalable base editor platform- GEMMABio will utilize a nonviral approach, encapsulating mRNA coding for Profluent's base-editing machinery into lipid nanoparticles to target hepatocytes- The award will support research
More news about: GEMMA Biotherapeutics
Jul 09, 2026, 12:38 ET DIA AND MHRA LAUNCH NEW GLOBAL REGULATORY SCIENCE SUMMIT IN LONDON TO ADVANCE SAFER AND SMARTER HEALTH INNOVATION
days, the programme will feature keynote addresses, panel discussions and case studies exploring next-generation medicines, including cell, gene and mRNA therapies. Sessions will also explore the future of clinical research, real-world evidence, AI-enabled healthcare, international regulatory alignment,
More news about: Drug Information Association
Jul 07, 2026, 10:00 ET New England Biolabs® launches the NEBNext® Companion Module for Oxford Nanopore Technologies® Direct RNA Sequencing
approaches that rely on sequencing the corresponding cDNA, including applications for identifying RNA modifications, tRNA sequencing, and characterization of mRNA for therapeutic purposes.Deyra Rodríguez, Ph.D., MBA, and Product Marketing Manager for NEB stated "We're extremely excited to see where direct
More news about: New England Biolabs, Inc.
Jul 06, 2026, 08:30 ET National Cold Vault Deploys Network-Isolated 4G LTE-M Telemetry to Eliminate Medical Spoliation in Public and Private Cold Chains
resulting in the silent spoliation of high-value biologics, dermal neurotoxins (Botox), GLP-1 agonists (Ozempic, Wegovy), and taxpayer-funded mRNA vaccines.National Cold Vault eliminates this structural flaw by bypassing local IT firewalls and facility power grids entirely. Utilizing dedicated,
More news about: National Cold Vault LLC
Jul 03, 2026, 04:03 ET Startup Island TAIWAN-Led Delegation Secures More Than 100 Business Meetings at BIO 2026, Expanding Global Opportunities for Taiwanese Biotech Startups
tumor recurrence. Its lead candidate, AM-928, is advancing through clinical development for solid tumors. The company also leverages proprietary mRNA-LNP technologies for vaccines and nucleic acid therapeutics, creating opportunities across oncology and infectious diseases.Website:
More news about: DCB
Jul 02, 2026, 21:36 ET Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based
More news about: Nona Biosciences
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
INCMGA00012), LN-145, Divarasib (GDC-6036), Fianlimab (REGN3767), Sacituzumab tirumotecan (MK-2870/SKB264), Eftilagimod alpha, Intismeran autogene (mRNA-4157/V940), Plinabulin, Zipalertinib, Olomorasib, Ceralasertib, TEDOPI, Sigvotatug vedotin, ANKTIVA, Pyrotinib, Volrustomig, TRODELVY (sacituzumab govitecan),
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 20:05 ET Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based
More news about: Nona Biosciences